Stroke Prevention in Atrial Fibrillation
VideosWebinarsKey ArticlesIndependent Medical EducationNew This MonthGuidelinesRandomised Controlled TrialsMeta-AnalysesReal World studiesDabigatranRivaroxabanEdoxabanApixabanDiabetesElderlyHypertensionValvular Heart DiseaseOther studiesReviewsSpecific Clinical IndicationsPractical Aspects of UseReversal AgentsStrategies
Literature review: stroke prevention in atrial fibrillation
The review includes the pivotal randomised controlled trials for warfarin and direct oral anticoagulants as well as relevant publications from the last 18 months. The following search terms were used: ‘stroke prevention’, ‘atrial fibrillation’, dabigatran, rivaroxaban, apixaban, edoxaban, warfarin, ‘oral anticoagulants’, ‘non-VKA oral anticoagulants’, novel oral anticoagulants’, ‘direct oral anticoagulants’, ‘reversal agents’
New This Month
-
Paolo Verdecchia, Maria Cristina Vedovati, Serenella Conti, et alVerdecchia P et al. Expert Opin Drug Saf. 27 September, 2018. Epub ahead of print.
-
Benjamin E. Peterson, Deepak L. BhattPeterson BE et al. Curr Cardiol Rep. 2018;20:110.
-
Gregg W Stone, JoAnn Lindenfeld, William T Abraham, et alStone GW, et al for the COAPT Investigators. N Engl J Med. 23 September, 2018. Epub ahead of print.
-
Jan SteffelSteffel J. Cardiol J. 2018;25:441-442.
Videos
-
14 November 2018 -
14 November 2018 -
14 November 2018 -
14 November 2018 -
14 November 2018 -
14 September 2018
Pages
Webinars
-
Dr Robert Byrne, Prof Georg Nickenig, Prof Stefan Hohnloser, Prof Georg Nickenig, Prof Pepe Zamorano, Dr Jose Lopez-Sendon. -
Gheorghe-Andrei Dan -
Dr. Amit Mistri
Key Articles
-
Jason G Andrade, Nathaniel M. Hawkins, Christopher B. Fordyce, et alAndrade JG al. Can J Cardiol. 2018. Article in press.
-
Deirdre A Lane, Juliane Meyerhoff, Ute Rohner, et alLane DA et al. Clin Cardiol. 2018;41:855-861. 12 June, 2018. Epub ahead of print.
-
Christina Ji-Young Lee, Thomas Alexander Gerds, Nicholas Carlson, et alLee CJ et al. J Am Coll Cardiol. 2018;72:17-26.
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
Independent Medical Education
-
Byrne R, Hohnloser S, Nickenig G, Sendon JL and Zamarano JL, Radcliffe-CME, Feb 2018. -
Harald Darius -
Torben Bjerregaard Larsen, Flemming Skjoth, Peter Bronnum Nielsen, et alBMJ 2016;353:i3189
-
Hugh Calkins, A John Camm
Guidelines/ Expert Recommendations
-
Gheorghe-Andrei Dan, Konstantinos Iliodromitis, Daniel Scherr, et alDan GA et al. Europace. 8 June, 2018. Epub ahead of print.
-
J. Steffel, Peter Verhamme, Tatjana S Potpara, et alSteffel J et al. Eur Heart J. 17 March, 2018. Epub ahead of print.
-
Gordon F. Tomaselli, Kenneth W. Mahaffey, Adam Cuker, et alTomaselli GF et al. J Am Coll Cardiol. 2017;70:3042-3067.
-
Craig T. January, Samuel Wann, Joseph S. Alpert, et alJ Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.
Randomised Controlled Trials
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
-
Emily C. O'Brien, DaJuanicia N. Holmes, Laine Thomas, et alO’Brien EC et al. J Am Heart Assoc. 2018;7:pii: e006391.
-
Luigi Di Biase, Jorge RomeroDi Biase L and Romero J. JACC Clin Electrophysiol. 2018;4:601-603.
-
Emmanuelle Duceppe, Salim Yusuf, Vikas Tandon, et alDuceppe E et al. Can J Cardiol. 2 February, 2018. pii: S0828-282X(18)30038-2. Epub ahead of print.
Meta-Analyses
-
Elgendy AY, Dhruv Mahtta, Amr F. Barakat, et alElgendy AY et al. Am J Cardiol. 2017, 8 August.
-
Kinjal Banerjee, Kanhaiya Poddar, Stephanie Mick, et alBanerjee K et al. Am J Cardiol. 2017, 1 August. pii: S0002-9149(17)31232-8.
-
Andreas Clemens, Mandy Fraessdorf, Jeffrey Friedman, et alVasc Health Risk Manag 2013;9:599-615
-
N. S. Roskell, Gregory YH Lip, Heiko Noack, et alThromb Haemost 2010;104:1106-15
Real World / Retrospective Studies
-
Marco Proietti, Cécile Laroche, Ole Nyvad, et alProietti M et al. Int J Cardiol. 2017;248:166-172.
-
Adrienne M. Gilligan, Pranav Gandhi, Xue Song, et alGilligan AM et al. Am J Cardiovasc Drugs. Published online 9 August, 2017.
-
Miney Paquette, Lionel Riou França, Christine Teutsch, et alPaquette M et al. J Am Coll Cardiol. 2017;70:1573-1583.
-
Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, et alHuisman et al. Am Heart J. 2017.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Dabigatran
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
-
Sara Själander, Vilhelm Sjögren, Henrik Renlund, et alSjälander S et al. Thromb Res. 2018;167:113-118.
-
Stephan Glund, Guanfa Gan, Viktoria Moschetti, et alGlund S et al. Clin Appl Thromb Hemost. 1 January, 2018: 1076029618755947. Epub ahead of print.
-
Jared Miller, Jeffrey A. Brinker, David D Spragg, et alMiller JD et al. Heart Rhythm Case Rep. 2017;3:566–567. eCollection, December, 2017.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Rivaroxaban
-
Sara Själander, Vilhelm Sjögren, Henrik Renlund, et alSjälander S et al. Thromb Res. 2018;167:113-118.
-
The Medical Letter, Inc. Med Lett Drugs Ther. 2018;60:99-101.
-
L. Staerk, Thomas Alexander Gerds, Gregory Y. H. Lip, et alStaerk L et al. J Intern Med. 2017, 21 September.
-
Siyang Peng, Kristen A. Deger, Anastasia Ustyugova, et alPeng S et al. Curr Med Res Opin. Published online 26 September, 2017.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Edoxaban
-
J. Steffel, Robert P Giugliano, Eugene Braunwald, et alEur Heart J. 2015 Sep 1;36(33):2239-45.
-
Erin A. Bohula, Robert P Giugliano, Christian T. Ruff, et alCirculation. 2016 Jul 5;134(1):24-36.
-
Robert P Giugliano, Christian T. Ruff, Stephen D. Wiviott, et alAm J Med. 2016 Aug;129(8):850-857.e2.
-
Natalia S. Rost, Robert P Giugliano, Christian T. Ruff, et alStroke. 2016 Aug;47(8):2075-82.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Apixaban
-
The Medical Letter, Inc. Med Lett Drugs Ther. 2018;60:99-101.
-
L. Staerk, Thomas Alexander Gerds, Gregory Y. H. Lip, et alStaerk L et al. J Intern Med. 2017, 21 September.
-
Craig I. Coleman, W Frank Peacock, Thomas J. Bunz, et alStroke. 2017;STROKEAHA.117.017474
-
Alpesh Amin, Allison Keshishian, Jeffrey Trocio, et alCurr Med Res Opin. 2017 Jul 11:1-10.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Diabetes
-
David A. McAllister, Stephanie Read, Jan Kerssens, et alCIRCULATIONAHA.118.034986. Epub ahead of print.
-
Michael E. Nassif, Mikhail KosiborodNassif ME and Kosiborod M. Circulation. 2018;138:4-6.
-
Shilpa Vijayakumar, Muthiah Vaduganathan, Javed Butler, et alVijaykumar S et al. Circulation. 2018;137:1060-1073.
-
Petar M Seferovic, Mark C. Petrie, Gerasimos Filippatos, et alSeferović PM et al. Eur J Heart Fail. 8 March, 2018. Epub ahead of print.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Elderly
-
Giuseppe Patti, Ilaria Cavallari, Olivier Hanon, et alPatti G et al. Int J Cardiol. 2018;265:118-124.
-
Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, et alYanagisawa S et al. JACC Clin Electrophysiol. 2018;4:592-600.
-
Giulia Magnani, Robert P Giugliano, Christian T. Ruff, et alEur J Heart Fail. 2016 Sep;18(9):1153-61.
-
Eri Toda Kato, Robert P Giugliano, Christian T. Ruff, et alJ Am Heart Assoc, 2016;5:. pii: e003432.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Hypertension
-
Meena P. Rao, Sigrun Halvorsen, Daniel M. Wojdyla, et alJ Am Heart Assoc. 2015 Dec 1;4(12). pii: e002015.
-
Sreekanth Vemulapalli, Anne S. Hellkamp, W. Schuyler Jones, et alAm Heart J. 2016 Aug;178:74-84.
-
Claudio Borghi, Stefania Paolillo, Arrigo FG Cicero, et alJ Hypertens. 2017 Apr;35(4):689-695.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Valvular
-
Michael D. Ezekowitz, Rangadham Nagarakanti, Herbert Noack, et alCirculation. 2016 Aug 23;134(8):589-98.
Other Studies
-
Deirdre A Lane, Juliane Meyerhoff, Ute Rohner, et alLane DA et al. Clin Cardiol. 2018;41:855-861. 12 June, 2018. Epub ahead of print.
-
Jeffrey Friedman, Andreas Clemens, D. Khadzhynov, et alThromb Haemost. 2013;109:596-605.
-
Stefan H Hohnloser, A John CammEuropace. 2013;15:1407-1411
-
Stuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz, et alCirculation. 2013;128:A10684
Reviews/Others
-
Darryl P. Leong, Philip G. Joseph, Martin McKee, et alLeong DP et al. Circ Res. 2017;121:695-710.
-
A. J. A. McLellan, Markus P SchlaichThromb Haemost 2013;109:580-1
-
Graeme J. Hankey, J. W. EikelboomCirculation 2011;123:1436-50
-
Gerald V Naccarelli, Mark J. Alberts, Richard A. Bernstein, et alStroke 2012;43:271-9
Specific Clinical Indications
-
C Fielder Camm, A John CammCamm CF et al. Arrhythm Electrophysiol Rev. 2017;6:53-68.
Practical Aspects of Use
-
Thomas F LüscherLüscher TF et al. Eur Heart J. 2017;38:2573-2575.
-
Eunice Yang, Esra Gucuk Ipek, Muhammad Balouch, et alYang E et al. Europace. 2017;19:241-249.
-
Andreas Goette, Hein HeidbuchelGoette A et al. Arrhythm Electrophysiol Rev. 2017;6:50-54.
-
Brystana G Kaufman, Sunghee Kim, Karen S. Pieper, et alKaufman BG et al. Heart. 2017, 8 Aug. pii: heartjnl-2017-311800.
Reversal Agents
-
António Tralhão, Carlos Aguiar, Jorge Ferreira, et alTralhão A et al. Thromb J. 2017;15:23.
Ablation strategies
-
Jason G Andrade, Nathaniel M. Hawkins, Christopher B. Fordyce, et alAndrade JG al. Can J Cardiol. 2018. Article in press.
-
Hugh Calkins, Gerhard Hindricks, Riccardo Cappato, et alCalkins H et al. Europace. 2017;0:1-52.
-
Naga Venkata Pothineni, Srikanth VallurupalliUS Cardiology Review 2018;12(2):103–6.DOI: https://doi.org/10.15420/usc.2017:39:1
-
Manav SohalEuropean Cardiology Review 2017;12(1):38–9.DOI: https://doi.org/10.15420/ecr.2017:10:2
-
Raymond B Fohtung, Michael W RichUS Cardiology Review 2016;10(2):60–4DOI: https://doi.org/10.15420/usc.2016:1:1
-
Piotr PonikowskiEuropean Cardiology Review,2012 ; (3):150
